Women's Health News

RSS

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Unnecessary cesarean section rates rising at both rural and urban hospitals

Rates of unnecessary cesarean section and other potentially risky obstetric procedures show some significant differences between rural and urban hospitals in the United States, reports a study in the January issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

13 Dec 2013

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

Women being treated with breast cancer drugs known as aromatase inhibitors can markedly ease the joint pain associated with the drugs by engaging in moderate daily exercise, Dana-Farber Cancer Institute and Yale University investigators report in a study to be presented during the San Antonio Breast Cancer Symposium.

13 Dec 2013

More outreach needed for family members who carry genetic risks of cancer

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves-despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

13 Dec 2013

Women who take shorter maternity leave may have increased risk of postpartum depression

The more leave time from work that a woman takes after giving birth -- up to six months -- the better protected she will be from experiencing post-partum depression, according to a study led by Dr. Rada K. Dagher, assistant professor of health services administration at the University of Maryland School of Public Health.

13 Dec 2013

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute, may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and aromatase inhibitors.

13 Dec 2013

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet.

13 Dec 2013

Researchers caution pregnant women about eating red and processed meats

Pregnant women and women planning to become pregnant can make use of the holiday season to adjust their diets and reduce the risk of gestational diabetes, according to researchers at the University of Adelaide's Robinson Institute.

13 Dec 2013

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Vast majority of women who have experienced gender-based violence remain uncounted: Study

Findings from a new global study suggest that estimates of gender-based violence prevalence based on health systems data or on police reports may underestimate the actual total prevalence by 11- to 128-fold. Led by Tia Palermo, PhD, Assistant Professor in Public Health and the Department of Preventive Medicine at Stony Brook University School of Medicine, the study is soon to be published online in the American Journal of Epidemiology.

12 Dec 2013

Vaginal delivery and early breast-feeding increase mothers' level of satisfaction

An article published in the journal Nutricion Hospitalaria reveals that the attitude of healthcare personnel, along with starting early breast-feeding, are another two factors that help in increasing the mothers' level of satisfaction

12 Dec 2013

Chiranjeevi Yojana program unsuccessful in reducing infant and maternal deaths in rural India

A prominent program that claims to reduce infant and maternal deaths in rural India by encouraging mothers to deliver in private hospitals has been unsuccessful, despite the investment of more than $25 million since 2005, a new Duke University study finds.

12 Dec 2013

Study: Younger women more likely to be hospitalized and die from acute myocardial infarction

Young women, ages 55 years or below, are more likely to be hospitalized for an acute myocardial infarction (AMI) and to die within the first 30 days than men in the same age group, according to a new study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

HSET protein could help doctors identify aggressive breast cancers in African-American patients

African-American women who get breast cancer often get more aggressive forms of the disease and at younger ages than other women.

12 Dec 2013

Report: Screen all endometrial cancer patients for Lynch syndrome

A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. Next to colorectal cancer, endometrial cancer is the most common form of cancer in women with Lynch syndrome.

12 Dec 2013

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Women's Health News

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Unnecessary cesarean section rates rising at both rural and urban hospitals

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

More outreach needed for family members who carry genetic risks of cancer

Women who take shorter maternity leave may have increased risk of postpartum depression

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Researchers caution pregnant women about eating red and processed meats

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Results from NeoALTTO trial to be presented at 2013 San Antonio Breast Cancer Symposium

Vast majority of women who have experienced gender-based violence remain uncounted: Study

Vaginal delivery and early breast-feeding increase mothers' level of satisfaction

Chiranjeevi Yojana program unsuccessful in reducing infant and maternal deaths in rural India

Study: Younger women more likely to be hospitalized and die from acute myocardial infarction

HSET protein could help doctors identify aggressive breast cancers in African-American patients

Report: Screen all endometrial cancer patients for Lynch syndrome

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News